Press Releases Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
1.58 ^USD	+2.60%		-4.24%	+3.27%

04-22	Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day
03-25	Lexicon Pharmaceuticals Files Prospectus for Secondary Offering	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lexicon Pharmaceuticals to Host 2024 Investor Day	04-18	AQ
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04-03	AQ
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo	03-25	AQ
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease	03-12	AQ
Lexicon: Q4 Earnings Snapshot	03-11	AQ
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update	03-11	AQ
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities	03-11	AQ
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA	03-11	AQ
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference	01-08	AQ
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference	12-21	AQ
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)	11-30	AQ
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference	11-22	AQ
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data	11-12	AQ
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference	11-10	AQ
Lexicon: Q3 Earnings Snapshot	11-08	AQ
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	11-08	AQ
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023	11-03	AQ
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023	11-02	AQ
INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients	11-01	AQ
Lexicon Strengthens Management Team With Two New Executives	31/10/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Press Releases

Filters